Research programme: thrombosis and coagulation disorder therapies - Thrombotargets

Drug Profile

Research programme: thrombosis and coagulation disorder therapies - Thrombotargets

Alternative Names: TT-105; TT-111; TT-112; TT-113; TT-114; TT-115; TT-116; TT-120; TT-123; TT-C01

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Thrombotargets Corporation
  • Class Monoclonal antibodies; Peptides; Recombinant proteins; Small molecules
  • Mechanism of Action Antifibrinolytic agents; Fibrinolytic agents; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Blood coagulation disorders; Thrombosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Coagulation-disorders in European Union (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for research development in Coagulation-disorders in European Union (Topical)
  • 04 Nov 2017 No recent reports of development identified for research development in Coagulation-disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top